Evaluation of myocardial functional parameters during intravenous cyclophosphamide pulse therapy: a case report.
Merico
Antonio
A
Levedianos
Giorgio
G
Gallo
Paolo
P
Zanco
Pierliugi
P
Piccione
Francesco
F
Tonin
Paolo
P
D013956:Antithyroid Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001418:Baclofen / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006321:Heart / Q000503:physiopathology*; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013318:Stroke Volume; D013616:Tachycardia, Sinus / Q000139:chemically induced* / Q000503:physiopathology
D013956:Antithyroid Agents; D007166:Immunosuppressive Agents; D008713:Methimazole; D003520:Cyclophosphamide; D001418:Baclofen